Dose-intensive weekly alternating chemotherapy for patients with small cell lung cancer: Randomized trial, can it improve survival of patients with good prognostic factors?

Oncology Reports

Volumn 7, Issue 2, 2000, Pages 305-310

  Kimasutani, Masayu ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CAV PE; Dose intensity; Good prognostic factor; Weekly chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; LUNG TUMOR; MALE; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SMALL CELL CARCINOMA; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CISPLATIN; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 0034145976     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (1)

1. Seifer EJ and Ihdc DC: Therapy of small cell lung cancer: A perspective on two decades of clinical research. Semin Oncol 15: 278-299, 1988.